社会经济因素与美国医保2型糖尿病患者司美格鲁肽或替尔泊肽起始治疗的关系
该横断面研究基于100% Medicare索赔数据,纳入13,922,387例≥65岁2型糖尿病患者,分析2023年司美格鲁肽或替尔泊肽起始治疗与自报种族/民族、双重参保、农村ity及社会脆弱指数的关联。结果显示,少数族裔身份、双重参保及居住于高社会脆弱社区与起始治疗几率降低相关。
要点
- 少数族裔身份与起始治疗几率降低相关(非西班牙裔黑人 vs 白人 aOR 0.72)。
- 双重参保(Medicare和Medicaid)与起始治疗几率降低相关(aOR 0.90)。
- 居住于最社会脆弱社区与起始治疗几率降低相关(aOR 0.93)。
核心结论
- 少数族裔身份和不利社会经济因素与Medicare 2型糖尿病患者起始司美格鲁肽或替尔泊肽的几率降低相关。
研究设计与样本
- 横断面研究,使用100% Medicare索赔数据,纳入≥65岁2型糖尿病患者13,922,387例。
主要发现
- 在13,922,387例2型糖尿病患者中,673,776例(4.8%)于2023年起始司美格鲁肽或替尔泊肽。
- 非西班牙裔黑人相比白人起始治疗的aOR为0.72(95% CI 0.71-0.72)。
- 双重参保者起始治疗的aOR为0.90(95% CI 0.89-0.91)。
- 居住于最社会脆弱社区相比最不脆弱社区起始治疗的aOR为0.93(95% CI 0.92-0.93)。
临床怎么用
- 识别少数族裔和不利社会经济因素患者,关注其起始司美格鲁肽或替尔泊肽的公平性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Identifying social and economic factors associated with initiation of semaglutide or tirzepatide may inform strategies to support equitable uptake. RESEARCH DESIGN AND METHODS: A cross-sectional study was conducted using 100% of Medicare claims of patients ≥65 years with type 2 diabetes mellitus (T2DM). The outcome was initiation of semaglutide or tirzepatide. We calculated adjusted odds ratios (aORs) for each exposure (self-reported race and ethnicity, dual enrollment in Medicare and Medicaid, rurality, and social vulnerability index), accounting for demographic and clinical characteristics. RESULTS: Among 13,922,387 patients with T2DM, 673,776 (4.8%) initiated semaglutide or tirzepatide in 2023. Minoritized racial and ethnic identity (e.g., non-Hispanic Black compared with White; aOR 0.72; 95% CI 0.71-0.72), dual enrollment (aOR 0.90; 0.89-0.91), and residence in the most versus least vulnerable socially vulnerable neighborhoods (aOR 0.93; 0.92-0.93) were associated with lower initiation. CONCLUSIONS: Minoritized racial and ethnic identity and adverse socioeconomic factors were associated with lower odds of initiation among Medicare beneficiaries with T2DM.
引用
- Decker SRR, Chaudhary RS, Inoue K, et al. Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. Diabetes Care. 2026. PMID: 41348220. doi:10.2337/dc25-1619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。